Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A compound of the formula



wherein R^1 represents

alkanoyl of C_2-C_{10} which is unsubstituted, or which is substituted by a phenyl, or which is substituted on other than the a-carbon atom by an amino or protected amino group; benzoyl or substituted benzoyl bearing one or two substituents each of which is independently halo, loweralkyl of C_1 -C_4, loweralkoxy of C_1-C_4 or phenyl;

an acyl derived from an a-amino acid or an acyl derived from a protected a-amino acid, said a-amino acid being selected from the group consisting of:

alanine,

arginine,

asparagine,

aspartic acid,

cysteine,

glutamic acid,

glutamine,

glycine,

histidine,

isoleucine,

leucine,

lysine,

methionine,

3-phenylalanine,

3-(p-chlorophenyl)alanine,

proline,

serine,

threonine,

tryptophan and

valine,

in either D- or L-form; or

an acyl derived from an a-amino acid as defined above which bears on the amine a substituent which is alkyl of C_1-C_{10}, benzyl, phenylbenzyl, or p-chlorobenzyl, with the proviso that the acyl derived from N-methyl-D-leucine is excluded;

R^2 represents hydrogen or an epivancosaminyl of the formula



wherein R^{2a} represents hydrogen or $-CH_2-$ R^3 and R^3 represents

hydrogen,

alkyl of C_1-C_{11},

alkyl of C_1-C_{11}-R^4, or

R^4-(linker$_{(0\text{ or }1)}$-R^4)$_{0\text{ or }1}$,

wherein each R^4 is independently phenyl or phenyl substituted by one or two substituents, each of which is independently halo, loweralkyl of C_1-C_8, loweralkoxy of C_1 - C_8, loweralkylthio of C_1-C_4 , or trifluoromethyl, and "linker" is -0-, $-CH_2-$, or $-O-(CH_2)n-$ wherein n is 1-3;

2. (Original) A compound of Claim 1 in which R^2 is an epivancosaminyl radical wherein R^{2a} represents hydrogen.

3. (Original) A compound of Claim 2 in which R^2 is an epivancosaminyl radical wherein R^{2a} represents $-CH_2-R_3$.

4. (Original) A compound of Claim 3 in which R^3 is p-biphenylyl.

5. (Original) A compound of Claim 3 in which R^3 is p-(pchlorophenyl) phenyl.

6. (Currently Amended) A pharmaceutical formulation comprising a compound of claim 1 ~~any of Claims 1-5~~ in combination with a pharmaceutically acceptable diluent or carrier.

7. (Original) A method of treating a bacterial infection in a host comprising the step of administering to the host an effective amount of a formulation of Claim 6.

8. (Original) A method of Claim 7 wherein the bacterial infection is attributable to a vancomycin-resistantenterococcus.

9. (Currently Amended) A compound of any of claim 1 ~~any of Claims 1-5~~ for use in antibacterial therapy.

10. (Currently Amended) A compound of claim 1 ~~any of Claims 1-5~~ for use in antibacterial therapy against vancomycin-resistantenterococcus.

11. (Currently Amended) A process for the preparation of a compound as claimed in claim 1 ~~any one of Claims 1-5~~ which comprises reacting a parent glycopeptide of the formula



wherein R^2 is as defined in Claim 1, with an activated ester of an alkanoic acid of the desired R^1 as defined in Claim 1, and if desired, thereafter reductively alkylating the NDISACC amine and/or forming a pharmaceutically acceptable salt.